GRCE Grace Therapeutics, Inc.: institutional ownership and insider trading
34 funds reported holding $10.5M of Grace Therapeutics, Inc. in their latest 13F filings; in Q2 2026 funds net sold $885K, with 9 new positions and 11 funds selling out; over the last 12 months insiders bought $616K and sold $0 on the open market.
Famous investors holding GRCE
- Ken Griffin (Citadel Advisors): $913K, 0.0% of the portfolio
- Two Sigma (Two Sigma Investments): $220K, 0.0% of the portfolio
Largest institutional holders of GRCE
- Cerity Partners LLC — $1.93M
- Eversept Partners, LP — $1.75M
- VANGUARD GROUP INC — $1.48M
- BANK OF AMERICA CORP /DE/ (BAC, BAC-PB, BAC-PE, BAC-PK, BAC-PL, BAC-PM, BAC-PN, BAC-PO, BAC-PP, BML-PG, BML-PH, BML-PJ, BML-PL) — $1.12M
- VANGUARD CAPITAL MANAGEMENT LLC — $935K
- CITADEL ADVISORS LLC — $913K
- Maven Securities LTD — $454K
- JANE STREET GROUP, LLC — $367K
- Birchview Capital, LP — $272K
- CANTOR FITZGERALD, L. P. — $227K
Recent GRCE insider trades
- Oct 19, 2026: Opaleye Management Inc. bought 4,256 shares ($8.00K)
- Oct 16, 2026: Opaleye Management Inc. bought 71,065 shares ($136K)
- Oct 12, 2026: Opaleye Management Inc. bought 14,632 shares ($29.7K)
- Oct 5, 2026: Opaleye Management Inc. bought 60,490 shares ($124K)
5%+ owners
- Opaleye Management Inc.: 13.1% (Schedule 13G, filed Aug 7, 2026)
- ADAR1 Capital Management GP, LLC: 9.9% (Schedule 13G/A, filed May 15, 2026)
- ADAR1 Capital Management, LLC: 9.9% (Schedule 13G/A, filed Aug 14, 2026)
- Nantahala Capital Management, LLC: 6.8% (Schedule 13G/A, filed Aug 14, 2026)